Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vesleteplirsen for Duchenne Muscular Dystrophy (MOMENTUM)
NCT04004065Phase 2Terminated
- Sponsor
- Sarepta Therapeutics
- Start
- Jun 2019
- Primary completion
- Oct 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 8
01
Overview
A Phase 2 trial of eteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Jun 2019; status: terminated.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04004065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004065.